呼吸道合胞病毒是引起儿童下呼吸道感染的主要原因,目前临床主要的治疗措施为对症支持治疗,尚缺乏特异性抗病毒药物和安全有效的预防措施。近年来,多种新型药物已经进入了临床研究后阶段,部分药物已上市。综述了治疗呼吸道合胞病毒的早期和新型抗病毒药物的研究进展以及呼吸道合胞病毒主动、被动免疫预防策略,旨在提高临床医生对儿童呼吸道合胞病毒防治策略的认识。

Respiratory syncytial virus (RSV) is the main cause of lower respiratory tract infection in infants. At present, the main clinical treatment measures for RSV were symptomatic support treatment, and there was still a lack of specific antiviral drug and safe and effective preventive measures. In recent years, many drugs have entered the post-clinical research phase, and some drugs have been on the market. This article reviews the research progress of early antiviral drug and new antiviral drug for the treatment of RSV, as well as the prevention strategies of active and passive immunity of RSV, in order to improve clinicians' understanding of the prevention and treatment strategies of children's RSV.

R985；R978.7

天津市医学重点学科(专科)建设项目(TJYXZDXK-040A)